Q-omics provides the consensus-scored LINC01197 profile across patient tissues and cancer cell-line models. LINC01197 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01197 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, LINC01197 RNA expression shows 19,169 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KICH, and PDAC as cancer lineages where LINC01197 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01197 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01197 survival associations across molecular data types. LINC01197 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01197 RNA expression–survival associations across cancer types. High LINC01197 expression shows unfavorable associations in KIRP and BLCA, but favorable associations in HNSC, KIRC, LUSC and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01197 RNA expression.
This table summarizes LINC01197 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01197. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01197 shows lower tumor expression in KICH, THCA, LUAD, BLCA, KIRP and UCEC. The KICH box plot shows higher LINC01197 RNA expression in normal versus tumor tissue (log2 FC = −1.567, t-test p < 0.001).
This table shows molecular features associated with LINC01197 in patient tissues and cancer cell lines. In patient samples, LINC01197 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
